{
  "docId": "019dd923-5ca1-7489-b638-42055a53b541",
  "docSlug": "1774c324fda45105",
  "documentTitle": "Pivoting to a High Quality Growth of Clinical Trials in China PharmaDJ x L.E.K. Clinical Development Report",
  "authorId": "LEK",
  "authorName": "L.E.K.",
  "documentKindSlug": "consulting-deck",
  "documentKindLabel": "Consulting deck",
  "sourceTypeSlug": "strategy_consulting",
  "sourceTypeLabel": "Strategy consulting",
  "presentationDate": null,
  "orientation": "landscape",
  "aspectRatio": 1.778,
  "pageNumber": 8,
  "pageCount": 58,
  "prevPage": 7,
  "nextPage": 9,
  "slideType": "industry_trends",
  "function": "summarize",
  "density": "dense",
  "nDataPoints": 0,
  "notes": "The slide uses a honeycomb layout to group regulatory initiatives. Color coding indicates the nature of the policy (R&D, Registration, Pricing/Market Access, Commercialization).",
  "elementsJson": [
    "headline_text",
    "process_diagram",
    "icon_grid",
    "footnote"
  ],
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019dd923-5ca1-7489-b638-42055a53b541/8",
  "deckHref": "/decks/019dd923-5ca1-7489-b638-42055a53b541",
  "deckJsonHref": "/decks/019dd923-5ca1-7489-b638-42055a53b541.json",
  "deckAnchorHref": "/decks/019dd923-5ca1-7489-b638-42055a53b541#slide-8",
  "components": [
    {
      "bbox": null,
      "kind": "callout",
      "text": "Over the past 5 years, Chinese government has initiated a series of policies for healthcare industry, mostly positive for innovative drugs",
      "attrs": null,
      "subkind": null,
      "toolName": "Visual emphasis",
      "toolSlug": "visual-emphasis",
      "confidence": null,
      "componentId": "019dd951-c7ca-701b-9cbc-ad01b9821252",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.5,
        "w": 0.8,
        "x": 0.05,
        "y": 0.3
      },
      "kind": "diagram",
      "text": "Honeycomb diagram of regulatory initiatives",
      "attrs": null,
      "subkind": "other",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "fead2cae-afca-4573-b59a-c7cd9bcdd1ae",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.15,
        "x": 0.82,
        "y": 0.2
      },
      "kind": "legend",
      "text": "Positive for innovative drugs, R&D related, Registration related, Pricing and market access related, Commercialization related",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d07ed27d-a854-456b-87ae-c10618e8fb64",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.3,
        "x": 0.03,
        "y": 0.21
      },
      "kind": "paragraph",
      "text": "Key regulatory initiatives impacting China pharmaceutical market* (2017-2021)",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "cadbc954-b7bf-4153-927b-254dda097bb8",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.9,
        "x": 0.03,
        "y": 0.88
      },
      "kind": "source-note",
      "text": "Note: *CTA: Clinical Trial Application; DIP: Diagnosis-Intervention Packet; DRG: Diagnosis Related Groups; GBA: The Greater Bay Area; ICH: The International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use; NRDL: National Reimbursement Drug List; RWE: Real World Evidence. Source: NMPA, L.E.K. analysis",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "8f8c1a53-6016-413f-8f30-4d9c1a76b158",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.9,
        "x": 0.03,
        "y": 0.05
      },
      "kind": "title",
      "text": "Favorable policy: Over the past 5 years, Chinese government has initiated a series of policies for healthcare industry, mostly positive for innovative drugs",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "bc3a7d5d-2ba3-4195-919d-127bffb07d8a",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 11,
      "from": 6,
      "beatId": "2e308d53-f564-4d1b-a207-755a279e3246",
      "arcName": "The Consultant's Gambit",
      "arcSlug": "consultants-gambit",
      "beatName": "Problem & Complication",
      "beatSlug": "consultants-gambit-problem-complication",
      "evidence": "The report discusses the challenges facing China's clinical development, including COVID-19 uncertainties and funding challenges.",
      "position": 1,
      "confidence": 0.8,
      "parentBeatName": "Complication",
      "parentBeatSlug": "complication"
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}